Anticoagulant activity of low-molecular-weight sulfated derivatives of galactomannan from Cyamopsis tetragonoloba (L.) seeds

Mestechkina, N. M.; Shcherbukhin, V. D.; Bannikova, G. E.; Варламов, В. П.; Дрозд, Н. Н.; Tolstenkov, A. S.; Makarov, V. A.; Тихонов, В. Е.

doi:10.1134/s0003683807060142

Cited by 1 publication

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chemically sulfated galactomannan ( 22 , Figure ) with various degrees of sulfation (0.7–1.4 per saccharide) displayed moderate to higher anticoagulant activity than dextran sulfate and curdlan sulfate (a sulfated β(1 → 3)‐linked glucan) . A study has shown that sulfated galactomannan could inhibit both FIIa and FXa, via a mechanism that is thought to be different to that of UFH …”

Section: Heparin Mimeticsmentioning

confidence: 99%

Heparin mimetics with anticoagulant activity

Al-Nahain

Ignjatović

Monagle

et al. 2018

Medicinal Research Reviews

View full text Add to dashboard Cite

Heparin, a sulfated polysaccharide belonging to the glycosaminoglycan family, has been widely used as an anticoagulant drug for decades and remains the most commonly used parenteral anticoagulant in adults and children. However, heparin has important clinical limitations and is derived from animal sources which pose significant safety and supply problems. The ever growing shortage of the raw material for heparin manufacturing may become a very significant issue in the future. These global limitations have prompted much research, especially following the recent well-publicized contamination scandal, into the development of alternative anticoagulants derived from non-animal and/or totally synthetic sources that mimic the structural features and properties of heparin. Such compounds, termed heparin mimetics, are also needed as anticoagulant materials for use in biomedical applications (e.g., stents, grafts, implants etc.). This review encompasses the development of heparin mimetics of various structural classes, including synthetic polymers and non-carbohydrate small molecules as well as sulfated oligo- and polysaccharides, and fondaparinux derivatives and conjugates, with a focus on developments in the past 10 years.

show abstract

Section: Heparin Mimeticsmentioning

confidence: 99%